Table 5: Changes in FMEDD, NO, ET-1, MDA, and SOD in newly diagnosed type 2 diabetes after treatment with nateglinide.

GroupBefore taking nateglinideAfter taking nateglinideDifference in levels before and after nateglinide treatmentP values

Number of patients (M/F)32 (19/13)32 (19/13)
FMEDDFasting .001
After glucose load .0002
NOFasting .001*
After glucose load 0.001*
ET-1Fasting .001*
After glucose load .001*
MDAFasting .001*
After glucose load .001*
SODFasting .001
After glucose load .0002

FMEDD: flow-mediated endothelium-dependent dilation; NO: nitric oxide; ET-1: endothelin-1; MDA: malondialdehyde; SOD: superoxide dismutase.
*Using nonparametric analysis method.